Clinical trial

Palbociclib With Everolimus + Exemestane In BC

NCT02871791

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-08-24

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2016-08-24Date precision: day

Registry last updated2022-08-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breastunresolved

Hormone Receptor (HR)-Positive Breast Cancerunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

EverolimusDRUG · verified · RxNorm: everolimus

ExemestaneDRUG · verified · RxNorm: exemestane

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Pfizercollaborator

Mapped research locations

BostonMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02871791 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.